S&P 500   3,894.87 (-0.18%)
DOW   31,558.08 (+0.07%)
QQQ   321.68 (-0.59%)
AAPL   126.50 (-1.01%)
MSFT   235.05 (-0.80%)
FB   265.39 (+0.18%)
GOOGL   2,079.25 (+0.46%)
TSLA   704.95 (-1.88%)
AMZN   3,143.58 (-0.08%)
NVDA   546.15 (-1.36%)
BABA   238.24 (-1.43%)
CGC   35.84 (+3.20%)
GE   13.06 (-0.38%)
MU   92.41 (-2.48%)
NIO   44.02 (-11.54%)
AMD   85.71 (-0.79%)
T   28.35 (+0.93%)
F   12.55 (+4.76%)
ACB   11.48 (+3.99%)
DIS   194.79 (-0.10%)
BA   224.42 (+0.01%)
NFLX   552.50 (+0.34%)
BAC   35.62 (-0.47%)
S&P 500   3,894.87 (-0.18%)
DOW   31,558.08 (+0.07%)
QQQ   321.68 (-0.59%)
AAPL   126.50 (-1.01%)
MSFT   235.05 (-0.80%)
FB   265.39 (+0.18%)
GOOGL   2,079.25 (+0.46%)
TSLA   704.95 (-1.88%)
AMZN   3,143.58 (-0.08%)
NVDA   546.15 (-1.36%)
BABA   238.24 (-1.43%)
CGC   35.84 (+3.20%)
GE   13.06 (-0.38%)
MU   92.41 (-2.48%)
NIO   44.02 (-11.54%)
AMD   85.71 (-0.79%)
T   28.35 (+0.93%)
F   12.55 (+4.76%)
ACB   11.48 (+3.99%)
DIS   194.79 (-0.10%)
BA   224.42 (+0.01%)
NFLX   552.50 (+0.34%)
BAC   35.62 (-0.47%)
S&P 500   3,894.87 (-0.18%)
DOW   31,558.08 (+0.07%)
QQQ   321.68 (-0.59%)
AAPL   126.50 (-1.01%)
MSFT   235.05 (-0.80%)
FB   265.39 (+0.18%)
GOOGL   2,079.25 (+0.46%)
TSLA   704.95 (-1.88%)
AMZN   3,143.58 (-0.08%)
NVDA   546.15 (-1.36%)
BABA   238.24 (-1.43%)
CGC   35.84 (+3.20%)
GE   13.06 (-0.38%)
MU   92.41 (-2.48%)
NIO   44.02 (-11.54%)
AMD   85.71 (-0.79%)
T   28.35 (+0.93%)
F   12.55 (+4.76%)
ACB   11.48 (+3.99%)
DIS   194.79 (-0.10%)
BA   224.42 (+0.01%)
NFLX   552.50 (+0.34%)
BAC   35.62 (-0.47%)
S&P 500   3,894.87 (-0.18%)
DOW   31,558.08 (+0.07%)
QQQ   321.68 (-0.59%)
AAPL   126.50 (-1.01%)
MSFT   235.05 (-0.80%)
FB   265.39 (+0.18%)
GOOGL   2,079.25 (+0.46%)
TSLA   704.95 (-1.88%)
AMZN   3,143.58 (-0.08%)
NVDA   546.15 (-1.36%)
BABA   238.24 (-1.43%)
CGC   35.84 (+3.20%)
GE   13.06 (-0.38%)
MU   92.41 (-2.48%)
NIO   44.02 (-11.54%)
AMD   85.71 (-0.79%)
T   28.35 (+0.93%)
F   12.55 (+4.76%)
ACB   11.48 (+3.99%)
DIS   194.79 (-0.10%)
BA   224.42 (+0.01%)
NFLX   552.50 (+0.34%)
BAC   35.62 (-0.47%)
Log in
NASDAQ:FGEN

FibroGen Stock Forecast, Price & News

$35.84
-14.69 (-29.07 %)
(As of 03/2/2021 12:44 PM ET)
Add
Compare
Today's Range
$34.04
Now: $35.84
$39.17
50-Day Range
$38.41
MA: $49.05
$55.72
52-Week Range
$22.65
Now: $35.84
$57.21
Volume171,316 shs
Average Volume626,615 shs
Market Capitalization$3.26 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.59
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
FibroGen logo

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FGEN
CUSIPN/A
Phone415-978-1200
Employees531
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$256.58 million
Book Value$6.14 per share

Profitability

Net Income$-76,970,000.00
Net Margins-191.78%

Miscellaneous

Market Cap$3.26 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.60 out of 5 stars

Medical Sector

558th out of 1,966 stocks

Pharmaceutical Preparations Industry

271st out of 772 stocks

Analyst Opinion: 3.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$35.84
-14.69 (-29.07 %)
(As of 03/2/2021 12:44 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











FibroGen (NASDAQ:FGEN) Frequently Asked Questions

Is FibroGen a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FibroGen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FGEN, but not buy additional shares or sell existing shares.
View analyst ratings for FibroGen
or view top-rated stocks.

What stocks does MarketBeat like better than FibroGen?

Wall Street analysts have given FibroGen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but FibroGen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting FibroGen?

FibroGen saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 8,050,000 shares, an increase of 15.0% from the December 31st total of 7,000,000 shares. Based on an average trading volume of 753,400 shares, the days-to-cover ratio is presently 10.7 days. Approximately 9.7% of the company's shares are short sold.
View FibroGen's Short Interest
.

When is FibroGen's next earnings date?

FibroGen is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for FibroGen
.

How were FibroGen's earnings last quarter?

FibroGen, Inc. (NASDAQ:FGEN) released its quarterly earnings results on Sunday, February, 28th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.35. The biopharmaceutical company earned $65 million during the quarter, compared to the consensus estimate of $100.82 million. FibroGen had a negative trailing twelve-month return on equity of 48.19% and a negative net margin of 191.78%. The company's revenue was up 712.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.12) EPS.
View FibroGen's earnings history
.

How has FibroGen's stock price been impacted by Coronavirus?

FibroGen's stock was trading at $35.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FGEN stock has decreased by 0.8% and is now trading at $35.13.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for FGEN?

8 brokers have issued 12 month price objectives for FibroGen's stock. Their forecasts range from $40.00 to $72.00. On average, they anticipate FibroGen's stock price to reach $53.57 in the next twelve months. This suggests a possible upside of 52.5% from the stock's current price.
View analysts' price targets for FibroGen
or view top-rated stocks among Wall Street analysts.

Who are FibroGen's key executives?

FibroGen's management team includes the following people:
  • Mr. James A. Schoeneck, Chairman (Age 63, Pay $751.63k)
  • Mr. Pat Cotroneo, Chief Financial Officer (Age 57, Pay $773.57k)
  • Dr. K. Peony Yu, Exec. Advisor to Chief Exec. Officer (Age 59, Pay $926.21k)
  • Dr. Elias Kouchakji, Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance (Age 65, Pay $863.19k)
  • Ms. Christine L. Chung, Sr. VP of China Operations (Age 53, Pay $701.09k)
  • Mr. Enrique A. Conterno, CEO & Director (Age 54)
  • Dr. Barry A. Berkowitz, Founder
  • Dr. Michael J. Martinelli, Sr. VP of Technical Devel.
  • Dr. Percy Carter M.B.A., Ph.D., Chief Scientific Officer
  • Ms. Karen L. Bergman, VP of Investor Relations & Corp. Communications

Who are some of FibroGen's key competitors?

What other stocks do shareholders of FibroGen own?

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

Who are FibroGen's major shareholders?

FibroGen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (10.14%), BlackRock Inc. (8.68%), Price T Rowe Associates Inc. MD (3.99%), Janus Henderson Group PLC (3.74%), Bank of New York Mellon Corp (1.96%) and First Trust Advisors LP (1.56%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, Enrique A Conterno, James A Schoeneck, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Thomas B Neff and Thomas F Kearns Jr.
View institutional ownership trends for FibroGen
.

Which major investors are selling FibroGen stock?

FGEN stock was sold by a variety of institutional investors in the last quarter, including Fiera Capital Corp, First Trust Advisors LP, Price T Rowe Associates Inc. MD, Dimensional Fund Advisors LP, Alliancebernstein L.P., New York State Common Retirement Fund, Rothschild & Co. Asset Management US Inc., and Candriam Luxembourg S.C.A.. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, and Thomas F Kearns Jr.
View insider buying and selling activity for FibroGen
or view top insider-selling stocks.

Which major investors are buying FibroGen stock?

FGEN stock was bought by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Vantage Consulting Group Inc, BlackRock Inc., Morgan Stanley, Brown Advisory Inc., Intercontinental Wealth Advisors LLC, Philadelphia Trust Co., and Bank of New York Mellon Corp.
View insider buying and selling activity for FibroGen
or or view top insider-buying stocks.

How do I buy shares of FibroGen?

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $35.13.

How much money does FibroGen make?

FibroGen has a market capitalization of $3.20 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

How many employees does FibroGen have?

FibroGen employs 531 workers across the globe.

What is FibroGen's official website?

The official website for FibroGen is www.fibrogen.com.

Where are FibroGen's headquarters?

FibroGen is headquartered at 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.